Correlation Between Armata Pharmaceuticals and Scopus Biopharma

Can any of the company-specific risk be diversified away by investing in both Armata Pharmaceuticals and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Armata Pharmaceuticals and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Armata Pharmaceuticals and Scopus Biopharma, you can compare the effects of market volatilities on Armata Pharmaceuticals and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Armata Pharmaceuticals with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Armata Pharmaceuticals and Scopus Biopharma.

Diversification Opportunities for Armata Pharmaceuticals and Scopus Biopharma

0.0

Correlation Coefficient

Armata Pharmaceuticals  Scopus Biopharma

Pay attention - limited upside

The 3 months correlation between Armata and Scopus is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Armata Pharmaceuticals and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Armata Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Armata Pharmaceuticals are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Armata Pharmaceuticals i.e., Armata Pharmaceuticals and Scopus Biopharma go up and down completely randomly.

Pair Corralation between Armata Pharmaceuticals and Scopus Biopharma

If you would invest (100.00) in Scopus Biopharma on December 28, 2024 and sell it today you would earn a total of  100.00  from holding Scopus Biopharma or generate -100.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Armata Pharmaceuticals  vs.  Scopus Biopharma

Armata Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Armata Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with abnormal performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Scopus Biopharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Armata Pharmaceuticals and Scopus Biopharma

The main advantage of trading using opposite Armata Pharmaceuticals and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Armata Pharmaceuticals position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.

The idea behind Armata Pharmaceuticals and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.